<DOC>
	<DOCNO>NCT02690454</DOCNO>
	<brief_summary>Ticagrelor direct-acting , reversible platelet P2Y12 receptor inhibitor recommend recent European Society Cardiology guideline patient acute coronary syndrome ( ACS ) ( class recommendation I , level evidence B ) . Ticagrelor inhibit platelet function strong , faster consistently clopidogrel , former standard antiplatelet therapy . In landmark PLATO trial ( Study PLATelet inhibition patient Outcomes ) , ticagrelor therapy compare clopidogrel treatment associate reduce occurrence major adverse cardiovascular event all-cause mortality , also result small , statistically significant , increase rate major bleeding . The optimum choice antiplatelet treatment , aim provide patient maximum protection ischemic event , minimize risk bleeding complication , challenge contemporary ACS therapy . The tool may help physicians facilitate clinical decision make platelet function testing . According guidance European American group expert , three currently recommend platelet function test , namely VerifyNow device , Multiplate analyzer Vasodilator Stimulated Phosphoprotein Phosphorylation ( VASP ) assay . It need emphasize none three method prefer others . So far study link pharmacokinetic analysis ticagrelor active metabolite comparative evaluation platelet reactivity . The aim trial ass relationship concentration ticagrelor active metabolite ( AR-C124910XX ) result three recommend platelet function test patient myocardial infarction . Patients receive GP IIb/IIIa receptor inhibitor exclude primary analysis . Statistical analysis : The correlation assess use correlation coefficient intraclass correlation coefficient . agreement result compare platelet function test measure use Kappa statistic Bland-Altman analysis .</brief_summary>
	<brief_title>Which Platelet Function Test Best Reflects In Vivo Plasma Concentrations Ticagrelor Its Active Metabolite ?</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Pathologic Processes</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>provision inform consent prior study specific procedure diagnosis acute STsegment elevation myocardial infarction acute nonSTsegment male nonpregnant female , age 1880 year old provision inform consent angiography PCI treatment ticlopidine , clopidogrel , prasugrel ticagrelor within 14 day study enrollment hypersensitivity ticagrelor current treatment oral anticoagulant chronic therapy lowmolecularweight heparin active bleed history intracranial hemorrhage recent gastrointestinal bleeding ( within 30 day ) history coagulation disorder platelet count less &lt; 100 x10^3/mcl hemoglobin concentration le 10.0 g/dl history moderate severe hepatic impairment history major surgery severe trauma ( within 3 month ) patient consider investigator risk bradycardic event second third degree atrioventricular block screen eligibility history asthma severe chronic obstructive pulmonary disease patient require dialysis manifest infection inflammatory state Killip class III IV screen eligibility respiratory failure history severe chronic heart failure ( NYHA class III IV ) concomitant therapy strong CYP3A inhibitor ( ketoconazole , itraconazole , voriconazole , telithromycin , clarithromycin , nefazadone , ritonavir , saquinavir , nelfinavir , indinavir , atazanavir ) strong CYP3A inducer ( rifampicin , phenytoin , carbamazepine , dexamethasone , phenobarbital ) within 14 day study treatment body weight 50 kg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>ticagrelor</keyword>
	<keyword>ticagrelor active metabolite ( AR-C124910XX )</keyword>
	<keyword>platelet function test</keyword>
	<keyword>flow cytometric VASP assay</keyword>
	<keyword>VerifyNow® device</keyword>
	<keyword>Multiplate® analyzer</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>Multiplate® ADPtest</keyword>
	<keyword>VerifyNow® PRUTest™</keyword>
	<keyword>Platelet VASP/P2Y12 assay</keyword>
</DOC>